Net earnings for the quarter were $553 million or $5.75 per diluted share.
In the fourth quarter, revenue totaled $4.1 billion, adjusted earnings per share reached $6.77, and free cash flow was $548 million.
Adjusted earnings per share which exclude amortization, restructuring charges and special items, were $6.77 in the quarter, down from $10.56 last year.
In the fourth quarter, revenue totaled $4.1 billion, adjusted earnings per share reached $6.77, and free cash flow was $548 million.
Revenue for the quarter was $4.1 billion, a decrease of 9.7% compared to last year due to declines in organic revenue of 10.3% and divestitures of 0.1%, partially offset by acquisitions of 0.6% and favorable foreign currency translation of 10 basis points.
The decrease in organic revenue was due to a 21.8% reduction from COVID testing partially offset by a 4.1% increase in the base business.
Our adjusted earnings per share guidance is $17.25 to $21.25 compared to 2021 adjusted earnings per share of $28.52. Free cash flow is expected to be between $1.7 billion to $1.9 billion compared to $2.6 billion in 2021.
We expect enterprise base business organic revenue to grow at a compound annual growth rate of 4% to 7% compared to 2021.
As we continue to emphasize profitable growth, we expect enterprise margin expansion of 30 to 50 basis points on average annually through the outlook period compared to 2021 which was approximately 14 and a half percent.
And finally, we expect adjusted earnings per share to grow at an 11% to 14% CAGR compared to 2020 -- '19 adjusted earnings per share of $11.32.
Revenue for the quarter was $1.5 billion, an increase of 3.9% compared to last year due to organic base business growth of 7.9% and acquisitions of 0.3%, partially offset by lower COVID testing performed through its centralized business of 4% and divestitures of 0.3%.
We expect drug development revenue to grow 7% to 9.5% compared to 2021.
